A neutral comparison of Mochi Health and Fifty 410 on advertised price, fees, and disclosures. Sorted facts, no preference, no “best overall.”
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Factor | Mochi Health | Fifty 410 |
|---|---|---|
| Advertised tirzepatide | ~$278 eff. | from ~$133, dose-tiered |
| Membership | ~$79/mo required | None |
| Pharmacy named? | No | Yes — ProRx (503A), BPI (503B) |
| Provenance | secondary | primary |
Fifty 410 is lower at most doses and names its pharmacies; Mochi bundles a required membership and structured programming for a higher effective price. The trade is coaching/structure (Mochi) vs. lower cost and pharmacy transparency (Fifty 410). Neither is FDA-approved.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.